The Role of Immunotherapy in Non-transplant Eligible Multiple Myeloma.

Front Oncol · 2020 · PMC7218111 · PMID 32435618

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The combination Elo-Vd showed a trend for an improved PFS, median PFS was 9.6 months with Elo-Vd vs. 6.9 months with Vd (HR 0.72, 95% CI 0.49–1.06).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.